The Molecular Imaging and Mass Spectrometry Platform aims primarily to provide advanced capabilities for the spatial characterization of molecules in biological tissues, offering key information for biomedical research, translational research, and related fields such as pharmacology, microbiology, and biotechnology.

Its versatility allows for both targeted and exploratory studies, facilitating the identification of biomarkers, the definition of molecular signatures, and the understanding of complex pathological mechanisms.

The platform integrates a set of next generation technologies, which currently include ultra high resolution magnetic resonance mass spectrometry, MALDI and ESI ionization, ultra high performance liquid chromatography, as well as specialized equipment for sample preparation and advanced software for processing, visualization, and interpretation of spatially resolved multi omics data.on.

The platform seeks to meet the growing demand for technologies that enable the integration of multi omics information (metabolomics, lipidomics, and proteomics) with spatial resolution. Ultra high resolution mass spectrometry, combined with techniques such as MALDI and ESI, offers a unique capability to identify biomarkers and study pathological mechanisms in situ.

Objectives of the MIMS Platform:

1. Promote high quality biomedical research, facilitating researchers’ access to advanced molecular imaging and mass spectrometry technologies, and ensuring high standards of rigour, reproducibility, and scientific excellence.
2. Foster innovation in diagnosis, prognosis, and personalized therapy through the identification of spatial biomarkers, in situ molecular characterization, and the integration of multi omics information into translational research projects.
3. Train and specialize research and technical staff, offering structured training, expert support, and learning pathways in advanced mass spectrometry techniques, molecular imaging, and related data analysis..
4. Promote synergies and strategic collaborations, internal and external, encouraging the participation of IdISBa in scientific networks, multicentre projects, and partnerships with research centres, hospitals, and universities at national and international levels, to maximize the use and impact of the infrastructure..
5. Ensure efficient and sustainable use of the equipment, optimizing management, maintenance, and shared use processes, and ensuring that the platform is fully integrated within the Institute’s platform ecosystem.

Services:

The platform offers a range of specialized activities aimed at molecular characterization and advanced analysis of biological samples using state‑of‑the‑art technologies. Services include:

• Molecular imaging by ultra‑high‑resolution magnetic resonance mass spectrometry, designed for the detection and spatial localization of metabolites and lipids in tissues, providing the precision and sensitivity required for detailed molecular composition studies..
• Molecular phenotyping by direct infusion (FIA) MRMS, enabling rapid and reliable analysis of metabolic and lipid profiles without prior separation, optimizing both time and data quality. 
• Liquid chromatography for metabolic and lipid compound analysis by MRMS, combining chromatographic separation with the ultra‑high resolution of mass spectrometry to ensure accurate and robust identification of components of interest.
• Data analysis and report generation, including processing, interpretation, and presentation of results in standardized formats, ensuring traceability and usefulness for research and development projects.

This set of services provides a high‑level scientific infrastructure designed to support biomedical studies, competitive projects, and technology‑transfer initiatives.

Resources and Equipment:

The laboratory is equipped with a magnetic resonance mass spectrometry system (ScimaX‑MRMS, Bruker) and an ultra‑high‑performance liquid chromatography system (UHPLC Elute+, Bruker). This next‑generation platform enables molecular characterization with exceptional resolution and accuracy, facilitating detailed analysis of complex compounds and supporting advanced studies in metabolomics, lipidomics, and proteomics.

In addition, the laboratory is equipped with specialized devices for mass spectrometry imaging (MSI), such as the Sprayer M3+ and the SubliMATE system (HTX Imaging Technologies). These instruments ensure homogeneous and controlled sample preparation, essential aspects for MSI analysis, and contribute to improved quality, reproducibility, and reliability of experimental results

• Ultra‑high‑resolution magnetic resonance mass spectrometry system: ScimaX‑MRMS (Bruker).
• Ultra‑high‑performance liquid chromatography system: UHPLC Elute+ (Bruker).
• Spray‑type system for matrix and compound application for MSI: Sprayer M3+ (HTX Imaging Technologies).
• High‑performance matrix sublimation system for MSI: SubliMATE (HTX Imaging Technologies).